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ABSTRACT
Melanoma is a recalcitrant disease in need of transformative therapuetics. 
The present study used a patient-derived orthotopic xenograft (PDOX) nude-
mouse model of melanoma with a BRAF-V600E mutation to determine the efficacy 
of temozolomide (TEM) combined with tumor-targeting Salmonella typhimurium 
A1-R. A melanoma obtained from the right chest wall of a patient was grown 
orthotopically in the right chest wall of nude mice to establish a PDOX model. Two 
weeks after implantation, 40 PDOX nude mice were divided into 4 groups: G1, 
control without treatment (n = 10); G2, TEM (25 mg/kg, administrated orally daily 
for 14 consecutive days, n = 10); G3, S. typhimurium A1-R (5 × 107 CFU/100 μl, 
i.v., once a week for 2 weeks, n = 10); G4, TEM combined with S. typhimurium 
A1-R (25 mg/kg, administrated orally daily for 14 consecutive days and 5 × 107 
CFU/100 μl, i.v., once a week for 2 weeks, respectively, n = 10). Tumor sizes were 
measured with calipers twice a week. On day 14 from initiation of treatment, all 
treatments significantly inhibited tumor growth compared to untreated control (TEM:  
p < 0.0001; S. typhimurium A1-R: p < 0.0001; TEM combined with S. typhimurium 
A1-R: p < 0.0001). TEM combined with S. typhimurium A1-R was significantly 
more effective than either S. typhimurium A1-R (p = 0.0004) alone or TEM alone 
(p = 0.0017). TEM combined with S. typhimurium A1-R could regress the melanoma 
in the PDOX model and has important future clinical potential for melanoma patients.
INTRODUCTION
Melanoma becomes a recalcitrant cancer when 
it metastasizes to regional lymph nodes, with a 5-year 
survival rate of 29% and 7% when it metastasizes to organs 
[1]. Dacarbazine and cisplatinum have been used to treat 
melanoma with limited efficacy [1–5]. Temozolomide 
(TEM) is an alkylating agent, had been widely used as 
a first-line chemotherapy for melanoma but with limited 
efficacy [1–5]. Although recently-developed immuno-
therapy has extended survival to some extent, the 5-year 
survival rate has not significantly increased [1–5]. There 
is still no cure for stage III and IV melanoma due to drug 
resistance, tumor heterogeneity and an immune-suppressed 
tumor microenvironment [5]. Therefore, more effective 
approaches to melanoma treatment are needed.
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Clinically-relevant mouse models of melanoma 
could permit evaluation of tailor-made therapy based 
on the patient-derived tumor. Our laboratory pioneered 
the patient-derived orthotopic xenograft (PDOX) nude 
mouse model with the technique of surgical orthotopic 
implantation (SOI), including pancreatic [6–9], breast 
[10], ovarian [11], lung [12], cervical [13], colon [14–16], 
stomach [17], sarcoma [18–22], and melanoma [23]. 
The tumor-targeting Salmonella typhimurium A1-R 
(S. typhimurium A1-R), developed by our laboratory 
[24], is auxotrophic for Leu-Arg, which prevents it from 
mounting a continuous infection in normal tissues. S. 
typhimurium A1-R was effective against primary and 
metastatic tumors as monotherapy in nude mouse models 
of major cancers including prostate [25, 26], breast 
[27– 29], lung [30, 31], pancreatic [8, 32–35], ovarian 
[36, 37] stomach  [38], and cervical cancer [39], as well 
as sarcoma cell lines [40–42] and glioma [43, 44], all of 
which are highly aggressive tumor models. In addition, S. 
typhimurium A1-R was effective against patient-derived 
orthotopic models of pancreatic cancer [8, 35], sarcoma 
[20–22] and melanoma [23]. 
In a previous study, we used the PDOX model of 
melanoma to test sensitivity to three molecularly-targeted 
drugs and one standard chemotherapeutic. A melanoma 
with a BRAF-V600E mutation was resected from the 
right chest wall of a patient. The melanoma was grown 
orthotopically in the right chest wall of nude mice to 
establish a PDOX model. Trametinib (TRA), a MEK 
inhibitor caused tumor regression.  In contrast, another 
MEK inhibitor, cobimetinib (COB), slowed but did not 
arrest growth or cause regression of the melanoma.  TEM 
could slow but not arrest tumor growth or cause regression. 
Vemrafenib (VEM), which targets the BRAF-V600E 
mutation would be considered to be a strong candidate for 
VEM as first-line therapy, was not effective. These results 
demonstrated the powerful precision of the PDOX model 
for cancer therapy, not achievable by genomic analysis 
alone [45].
The combination of S. typhimurium A1-R and 
cisplatinum (CDDP), both at low-dose, also significantly 
suppressed the growth of another melanoma PDOX with 
less side effects than high-dose CDDP monotherapy [23]. 
In the present study, we evaluated the efficacy of S. 
typhimurium A1-R alone and in combination with TEM 
on a PDOX model for melanoma with the BRAF-V600E 
mutation.
RESULTS AND DISCUSSION
All treatments significantly inhibited tumor growth 
compared to untreated control (TEM: p < 0.0001; 
S. typhimurium A1-R: p < 0.0001; TEM combined 
with S. typhimurium A1-R: p < 0.0001) on day 14 after 
initiation. TEM combined with S. typhimurium A1-R was 
significantly more effective than both S. typhimurium 
A1-R (p = 0.0004) and TEM alone (p = 0.0017) and 
regressed the tumor. There was no significant difference 
between the efficacy of S. typhimurium A1-R and TEM 
on the melanoma PDOX (p = 0.5205) (Figures 1, 2). The 
relative body weight on day 14 compared with day 0 did 
not significantly differ between each treatment group 
(Figure 3).
Confocal microscopy showed that the S. 
typhimurium A1-R could directly target the melanoma 
PDOX (Figure 4) and cause tumor necrosis (Figure 5). 
The histology of the original patient tumor and the 
untreated PDOX tumor were similar, containing the same 
types of cells. However, nests of cancer cells were seen 
in the original, but not in the PDOX.  Also, the original 
tumor was slightly melanotic, but the PDOX tumor did not 
appear to contain melanin [45]. 
TEM, an alkylating agent, had been widely used 
as a standard chemotherapy for melanoma. Currently, 
several molecular targeting agents or immunotherapy are 
often the first line for melanoma treatment. However, not 
all melanomas have mutations that are targeted by these 
new agents and not all patients with these mutations are 
responsive to these drugs [1].
We previously showed with the present melanoma 
PDOX that TRA, a MEK inhibitor, was very active and 
could arrest this tumor, but that COB, another MEK 
inhibitor, could not arrest the melanoma PDOX. In addition, 
we showed the VEM was inactive against this melanoma 
PDOX [45], even though it targets the BRAF-V600E 
mutation in this melanoma [46].
Despite progress in melanoma therapy, there is still 
no cure for stage III and IV disease due to drug resistance, 
tumor heterogeneity and an immunosuppressive tumor 
microenvironment [1–5]. In addition, the presence of 
melanin appears to interfere with chemotherapy and 
radiotherapy of this recalcitrant disease [3]. The present 
results demonstrate the potential of S. typhimurium A1-R 
to significantly increase the efficacy of first-line melanoma 
therapy, TEM. 
MATERIALS AND METHODS
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. 
All mouse surgical procedures and imaging were 
performed with the animals anesthetized by subcutaneous 
injection of a ketamine mixture (0.02 ml solution of 
20 mg/kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg 
acepromazine maleate). The response of animals during 
surgery was monitored to ensure adequate depth of 
anesthesia. The animals were observed on a daily basis 
and humanely sacrificed by CO2 inhalation if they met the 
following humane endpoint criteria: severe tumor burden 
(more than 20 mm in diameter), prostration, significant 
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Figure 1: Macroscopic demonstration of therapeutic efficacy of TEM and S. typhimurium A1-R on a melanoma PDOX. 
(A) Tumor size of the untreated control mice increased over time. (B, C) Tumors treated with TEM or S. typhimurium A1-R were inhibited. 
(D) Tumors treated with TEM combined with S. typhimurium A1-R regressed. Yellow arrows show PDOX tumors on right chest wall. 
Scale bar: 20 mm. 
Figure 2: TEM combined with S. typhimurium A1-R regressed a melanoma PDOX model.  Line graph shows relative tumor 
volume at each point relative to the initial tumor volume. TEM combined with S. typhimurium A1-R significantly regressed tumor growth 
compared to both untreated control and monotherapy of either agent.  **p < 0.01. Error bars: ± SD.
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body weight loss, difficulty breathing, rotational motion 
and body temperature drop. Animals were housed in a 
barrier facility on a high efficacy particulate arrestance 
(HEPA)-filtered rack under standard conditions of 
12-hour light/dark cycles. The animals were fed an 
autoclaved laboratory rodent diet. All animal studies 
were conducted in accordance with the principles and 
procedures outlined in the National Institutes of Health 
Figure 3: Effect of TEM combined with S. typhimurium A1-R on mouse body weight.  Bar graph shows relative body weight in 
each treatment group at pre- and post-treatment relative to initial body weight. There were no significant differences between any of the 
treatment groups and control.
Figure 4: Fluorescence imaging of S. typhimurium A1-R-GFP targeting the melanoma PDOX. Confocal imaging with the FV1000 
demonstrated S. typhimurium A1-R-GFP targeting the melanoma PDOX. Bars: left panel: 5 mm, right panel: 12.5 μm. 
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Guide for the Care and Use of Animals under Assurance 
Number A3873-1.
Patient-derived tumor
A 75-year-old female patient diagnosed with a 
melanoma of the right chest wall. The tumor was resected 
in the Department of Surgery, University of California, 
Los Angeles (UCLA). Written informed consent was 
provided by the patient, and the Institutional Review 
Board (IRB) of UCLA approved this experiment [45].
Establishment of PDOX models of melanoma by 
surgical orthotopic implantation (SOI)
A fresh sample of the melanoma of the patient was 
obtained and transported immediately to the laboratory 
at AntiCancer, Inc., on wet ice. The sample was cut 
into 5-mm fragments and implanted subcutaneously 
in nude mice. After three weeks, the subcutaneously-
implanted tumors grew to more than 10 mm in diameter. 
The subcutaneously-grown tumors were then harvested 
and cut into small fragments (3 mm3). After nude mice 
were anesthetized with the ketamine solution described 
above, a 5-mm skin incision was made on the right chest 
into the chest wall, which was split to make space for 
the melanoma tissue fragment. A single tumor fragment 
was implanted orthotopically into the space to establish 
the PDOX model. The wound was closed with a 6–0 
nylon suture (Ethilon, Ethicon, Inc., NJ, USA) [45].
Preparation and administration of  
S. typhimurium A1-R
GFP-expressing S. typhimurium A1-R bacteria 
(AntiCancer Inc.,) were grown overnight on LB medium 
(Fisher Sci., Hanover Park, IL, USA) and then diluted 
1:10 in LB medium. Bacteria were harvested at late-log 
phase, washed with PBS, and then diluted in PBS. S. 
typhimurium A1-R was injected intravenously. A total 
of 5 × 107 CFU S. typhimurium A1-R in 100 μl PBS was 
administered to each mouse [25–27].
Treatment study design in the PDOX model of 
melanoma
PDOX mouse models were randomized into four 
groups of 10 mice each: untreated control (n = 10); 
treated with TEM (25 mg/kg, administrated orally 
daily for 14 consecutive days, n = 10) [1]; treated with 
S. typhimurium A1-R (5 × 107 CFU/100 μl, i.v., once a 
week for 2 weeks, n = 10); treated with TEM (25 mg/kg, 
administrated orally daily for 14 consecutive days) 
combined with S. typhimurium A1-R (5 × 107 CFU/100 μl, 
i.v., once a week for 2 weeks, n = 10). Tumor length and 
width were measured twice a week. Tumor volume was 
calculated with the following formula: Tumor volume 
(mm3) = length (mm) × width (mm) × width (mm) × 1/2. 
Data are presented as mean ± SD. The tumor volume ratio 
is defined at the tumor volume at any given time point 
relative to the initial tumor volume.  
Confocal microscopy
The FV1000 confocal microscope (Olympus, Tokyo, 
Japan) was used for high-resolution imaging. Fluorescence 
images were obtained using the 20×/0.50 UPlan FLN and 
40×/1.3 oil Olympus UPLAN FLN objectives [47].
Histological examination
Fresh tumor samples were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (5 μm) were deparaffinized in xylene and 
rehydrated in an ethanol series. Hematoxylin and eosin 
(H&E) staining was performed according to standard 
protocols. Histological examination was performed with a 
BHS System Microscope (Olympus Corporation, Tokyo, 
Japan). Images were acquired with INFINITY ANALYZE 
software (Lumenera Corporation, Ottawa, Canada) [20].
Figure 5: Tumor histology. (A) Untreated control was comprised of viable cells without obvious necrosis. (B) Tumor treated with 
S. typhimurium A1-R had significant necrosis. (C) Tumor treated with the combination of TEM and S. typhimurium A1-R showed more 
necrosis. White allows: necrotic areas. Scale bars: 100 μm. 
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Statistical analysis
JMP version 11.0 was used for all statistical 
analyses. Significant differences for continuous variables 
were determined using the Mann-Whitney U test. Line 
graphs expressed average values and error bar showed SD. 
A probability value of P ≤ 0.05 was considered statistically 
significant. 
CONCLUSIONS
The combination of TEM and S. typhimurium A1-R 
was more effective than each mono-therapy for melanoma 
in a PDOX mouse model and could regress the tumor. This 
treatment strategy has important future clinical application, 
which possibly can be realized in the near future. 
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [48–53]. 
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